Sanofi
CIK 1121404 · last filed 2021-09-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$10.54B
Companies
11
Total Filings
65
Lifetime Open-Market Net
-$2.44B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Translate Bio, Inc. (TBIO) Delisted | 10%+ Owner | 3,064,003 | $0.00 | $306 | $2.74B | 1 | 2021-09-14 |
| Icosavax, Inc. (ICVX) Delisted | 10%+ Owner | 3,155,169 | $15.31 | $48.31M | $1.00M | 1 | 2021-08-02 |
| Inozyme Pharma, Inc. (INZY) Delisted | 10%+ Owner | 438,875 | $4.00 | $1.76M | $1.30M | 1 | 2020-07-29 |
| REGN | 10%+ Owner | 279,766 | $694.59 | $194.32M | -$9.52B | 46 | 2020-06-11 |
| FULC | 10%+ Owner | 464,285 | $3.60 | $1.67M | $1.50M | 1 | 2019-07-23 |
| MyoKardia, Inc. (MYOK) Delisted | 10%+ Owner | 0 | — | — | -$121.48M | 5 | 2019-02-15 |
| ALNY | 10%+ Owner | 10,554,134 | $286.68 | $3.03B | $1.98B | 6 | 2017-06-01 |
| VYGR | 2,352,941 | $3.02 | $7.11M | $1.75M | 1 | 2015-11-18 | |
| Regulus Therapeutics Inc. (RGLS) Delisted | 10%+ Owner | 42,115 | $8.16 | $343.7K | $10.00M | 1 | 2014-02-05 |
| HUMANIGEN, INC (KBIO) Delisted | 579,030 | — | — | $700.0K | 1 | 2013-02-07 | |
| GENZ | 10%+ Owner | 187,986,225 | $38.87 | $7.31B | $2.48B | 1 | 2011-04-08 |
Recent Filings · Page 3 of 7
65 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-06-16 | REGN | Buy (P) | +64,731 | $23.55M | EDGAR |
| 2016-02-18 | REGN | Buy (P) | +161,157 | $63.25M | EDGAR |
| 2016-02-03 | ALNY | Buy (P) | +205,030 | $14.30M | EDGAR |
| 2016-01-14 | REGN | Buy (P) | +83,938 | $39.03M | EDGAR |
| 2015-11-18 | VYGR | Mixed | +2,477,941 | $1.75M | EDGAR |
| 2015-11-05 | MyoKardia, Inc. (MYOK) Delisted | Mixed | +3,218,899 | $9.00M | EDGAR |
| 2015-10-08 | REGN | Buy (P) | +80,538 | $37.02M | EDGAR |
| 2015-10-08 | REGN | Buy (P) | +11,040 | $5.21M | EDGAR |
| 2015-09-25 | REGN | Buy (P) | +147,209 | $78.71M | EDGAR |
| 2015-07-29 | REGN | Buy (P) | +10,639 | $5.72M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.